NovoCure Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Ashley Cordova
Chief executive officer
US$6.3m
Total compensation
| CEO salary percentage | 8.3% |
| CEO tenure | no data |
| CEO ownership | 0.08% |
| Management average tenure | 1.3yrs |
| Board average tenure | 7.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$150m |
| Jun 30 2024 | n/a | n/a | -US$169m |
| Mar 31 2024 | n/a | n/a | -US$193m |
| Dec 31 2023 | US$6m | US$525k | -US$207m |
| Sep 30 2023 | n/a | n/a | -US$197m |
| Jun 30 2023 | n/a | n/a | -US$174m |
| Mar 31 2023 | n/a | n/a | -US$141m |
| Dec 31 2022 | US$7m | US$508k | -US$93m |
| Sep 30 2022 | n/a | n/a | -US$82m |
| Jun 30 2022 | n/a | n/a | -US$68m |
| Mar 31 2022 | n/a | n/a | -US$59m |
| Dec 31 2021 | US$5m | US$478k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$27m |
| Jun 30 2021 | n/a | n/a | -US$5m |
| Mar 31 2021 | n/a | n/a | US$12m |
| Dec 31 2020 | US$3m | US$367k | US$20m |
Compensation vs Market: Ashley's total compensation ($USD6.32M) is above average for companies of similar size in the German market ($USD2.04M).
Compensation vs Earnings: Ashley's compensation has been consistent with company performance over the past year.
CEO
Ashley Cordova (45 yo)
no data
Tenure
US$6,317,066
Compensation
Ms. Ashley Cordova serves as Chief Executive Officer of NovoCure Limited since January 1, 2025 and had been its Chief Financial Officer since September 01, 2020 until January 1, 2025. Ms. Cordova is respon...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 21yrs | US$1.43m | 0.51% € 15.6m | |
| Chief Executive Officer | no data | US$6.32m | 0.085% € 2.6m | |
| General Counsel | 2.8yrs | US$4.86m | 0.020% € 617.4k | |
| Executive VP & President of Novocure Oncology | 4.3yrs | US$5.04m | 0.055% € 1.7m | |
| Founder & CTO | 25yrs | US$282.51k | no data | |
| Chief Financial Officer | no data | no data | 0.010% € 316.0k | |
| Chief Operating Officer | less than a year | no data | 0.0032% € 97.7k | |
| VP of Investor Relations | no data | no data | no data | |
| Chief Human Resources Officer | 1.3yrs | no data | 0.012% € 379.8k | |
| Chief Innovation Officer | 2yrs | no data | 0.057% € 1.7m | |
| Senior VP | no data | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
1.3yrs
Average Tenure
50.5yo
Average Age
Experienced Management: 038's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 21yrs | US$1.43m | 0.51% € 15.6m | |
| Independent Director | 6.5yrs | US$446.09k | 0.0023% € 71.4k | |
| Independent Director | 6.7yrs | US$426.09k | 0.0084% € 258.0k | |
| Director | 13yrs | US$1.52m | 0.014% € 441.2k | |
| Independent Director | 3.9yrs | US$448.53k | 0.0036% € 110.8k | |
| Independent Director | 13.3yrs | US$435.53k | 0.073% € 2.2m | |
| Lead Independent Director | 19yrs | US$475.53k | 0.15% € 4.5m | |
| Independent Director | 7.7yrs | US$446.09k | 0.014% € 440.9k | |
| Independent Director | 1.8yrs | US$696.94k | 0% € 0 | |
| Independent Director | 1.9yrs | US$697.26k | 0% € 0 |
7.2yrs
Average Tenure
62yo
Average Age
Experienced Board: 038's board of directors are considered experienced (7.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 19:10 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NovoCure Limited is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Gilbert | Deutsche Bank |
| Vijay Kumar | Evercore ISI |
| Emily Bodnar | H.C. Wainwright & Co. |